GE builds Japanese distribution with NEC deal
GE Medical Systems has signed an agreement with NEC Medical Systems of Tokyo to acquire NEC’s Japanese distribution organization. The deal calls for a joint marketing and distribution network to be established for the firms’ products and
GE Medical Systems has signed an agreement with NEC Medical Systems of Tokyo to acquire NECs Japanese distribution organization. The deal calls for a joint marketing and distribution network to be established for the firms products and services, with GE holding a majority stake in the network. With the agreement, GE adds to its $1 billion operation in Japan, according to executives at GE Medical Systems Asia. GEs Asia-Pacific division manages 10 joint ventures, and has 150 offices and more than 3500 employees.
Under the terms of the deal, NECs Japanese sales offices and its 350 salespeople will be transferred to the joint operation. The network will furnish Asian healthcare facilities with monitoring systems for adult, fetal, and neonatal patients, ECG units, and clinical information systems from GE Marquette Medical Systems. Patient monitors, cardiovascular products, and cerebral nerve diagnostic equipment will come from NEC. GE Marquette products will also continue to be distributed in Japan through existing channels, the company said.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
